Somatic mutation of the tumor suppressor gene TP53, located in 17p13, is frequently detected in patients with therapy-related AML [60, 61] or AML with complex karyotype or monosomal karyotype (53–73%) [62–65], in contrast to 7–8% in de novo AML patients [19, 65]. Here, TP53 is linked to acute myeloid leukemia.